ACROFAN

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020

Published : Thursday, February 11, 2021, 1:05 pm
ACROFAN=Businesswire | webmaster@businesswire.com | SNS

SAN DIEGO--(BUSINESS WIRE)--$ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2020.


Record fourth quarter revenue reflects a strong close to 2020:

  • Revenue of $953 million, an increase of 20% compared to the third quarter of 2020 and $0.5 million higher compared to the prior year period
  • GAAP net income attributable to Illumina stockholders for the quarter of $257 million, or $1.75 per diluted share, compared to $239 million, or $1.61 per diluted share, for the prior year period
  • Non-GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.22 per diluted share, compared to $252 million, or $1.70 per diluted share, for the prior year period. Non-GAAP net income excludes net gains from mark-to-market adjustments on our strategic investments, primarily from our marketable equity securities (see the “Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures)
  • Cash flow from operations of $406 million compared to $443 million in the prior year period
  • Free cash flow (cash flow from operations less capital expenditures) of $344 million for the quarter compared to $386 million in the prior year period

“Illumina delivered a strong finish to 2020 with record fourth quarter revenue exceeding our expectations,” said Francis deSouza, Chief Executive Officer. “We also had record orders in the quarter, including record sequencing instrument orders and the second highest quarter for NovaSeq instrument orders. Our business delivered strong sequential growth in the second half of 2020 and we expect continued recovery from the pandemic in 2021.”

Gross margin in the fourth quarter of 2020 was 66.1% compared to 69.5% in the prior year period. Excluding amortization of acquired intangible assets and expenses related to COVID-19, non-GAAP gross margin was 66.9% for the fourth quarter of 2020 compared to 70.2% in the prior year period.

Research and development (R&D) expenses for the fourth quarter of 2020 were $200 million compared to $161 million in the prior year period. Non-GAAP R&D expenses as a percentage of revenue were 20.9% compared to 16.8% in the prior year period.

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2020 were $298 million compared to $233 million in the prior year period. Excluding acquisition-related expenses, expenses related to COVID-19, and gain on litigation, non-GAAP SG&A expenses as a percentage of revenue were 25.1% compared to 22.2% in the prior year period.

Depreciation and amortization expenses were $50 million and capital expenditures for free cash flow purposes were $62 million during the fourth quarter of 2020. At the close of the quarter, the company held $3.5 billion in cash, cash equivalents and short-term investments, compared to $3.4 billion as of December 29, 2019.

Fiscal year 2020 results:

  • Revenue of $3,239 million, a 9% decrease compared to $3,543 million in fiscal 2019
  • GAAP net income attributable to Illumina stockholders of $656 million, or $4.45 per diluted share, compared to $1,002 million, or $6.74 per diluted share, in fiscal 2019
  • Non-GAAP net income attributable to Illumina stockholders of $664 million, or $4.50 per diluted share, compared to $976 million, or $6.57 per diluted share, in fiscal 2019 (see the “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures)
  • Cash flow from operations of $1,080 million compared to $1,051 million in fiscal 2019
  • Free cash flow (cash flow from operations less capital expenditures) of $891 million, compared to $842 million in fiscal 2019

Gross margin for fiscal 2020 was 68.0% compared to 69.6% in the prior year. Excluding amortization of acquired intangible assets, expenses and income related to COVID-19, and restructuring, non-GAAP gross margin was 69.0% for fiscal 2020 compared to 70.6% in the prior year period.

R&D expenses for fiscal 2020 were $682 million compared to $647 million in the prior year. Excluding expenses and income related to COVID-19, non-GAAP R&D expenses as a percentage of revenue were 21.0% compared to 18.2% in the prior year period.

SG&A expenses for fiscal 2020 were $941 million compared to $835 million in the prior year period. Excluding amortization of acquired intangible assets, acquisition-related expenses, expenses and income related to COVID-19, gain on litigation, and restructuring, non-GAAP SG&A expenses as a percentage of revenue were 24.6% compared to 22.0% in the prior year period.

Updates since our last earnings release:

  • Expanded NextSeq 2000 flow cell offering with launch of the P3 Reagent Kit and started shipping the NextSeq 1000
  • Announced TSO 500 partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to advance comprehensive genomic profiling
  • Launched Illumina Connected Analytics enabling customers to manage, analyze, and explore large volumes of multi-omic data in a secure, scalable, and flexible environment
  • Partnered with Harvard Pilgrim Health Care to expand access to whole-genome sequencing for genetic disease testing
  • Won patent infringement suit against BGI in the United Kingdom
  • Repurchased approximately $280 million of common stock in the fourth quarter with $15 million remaining for repurchase under our current plan
  • Announced a collaboration with Sequoia Capital China to catalyze the genomic startup ecosystem in China

Financial outlook and guidance

The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance. Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and non-GAAP financial measures.

For fiscal 2021, the company expects year-over-year revenue growth in the range of 17% to 20%, and expects GAAP earnings per diluted share of $4.76 to $5.01 and non-GAAP earnings per diluted share of $5.10 to $5.35. This guidance excludes the potential impact from the pending acquisition of GRAIL, which we expect to close in the second half of 2021.

Quarterly conference call information

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, February 11, 2021. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the “Company” tab at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with conference ID 3809129.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.

Statement regarding use of non-GAAP financial measures

The company reports non-GAAP results for diluted net income per share, net income, gross margins, operating expenses, operating margins, other income, and free cash flow in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company’s financial measures under GAAP include substantial charges such as amortization of acquired intangible assets, non-cash interest expense associated with the company’s convertible debt instruments that may be settled in cash, and others that are listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Additionally, non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders are key components of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) the impact to our business and operating results of the COVID-19 pandemic; (ii) changes in the rate of growth in the markets we serve; (iii) the volume, timing and mix of customer orders among our products and services; (iv) our ability to adjust our operating expenses to align with our revenue expectations; (v) the outcome of the pending acquisition of GRAIL, Inc.; (vi) our ability to manufacture robust instrumentation and consumables; (vii) the success of products and services competitive with our own; (viii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (ix) the impact of recently launched or pre-announced products and services on existing products and services; (x) our ability to further develop and commercialize our instruments and consumables, to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xi) our ability to obtain regulatory clearance for our products from government agencies; (xii) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xiii) our ability to successfully identify and integrate acquired technologies, products, or businesses; and (xiv) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Illumina, Inc.

Condensed Consolidated Balance Sheets

(In millions)

 

 

January 3,
2021

December 29,
2019

ASSETS

(unaudited)

 

Current assets:

 

 

Cash and cash equivalents

$

1,810

 

$

2,042

 

Short-term investments

1,662

 

1,372

 

Accounts receivable, net

487

 

573

 

Inventory

372

 

359

 

Prepaid expenses and other current assets

152

 

105

 

Total current assets

4,483

 

4,451

 

Property and equipment, net

922

 

889

 

Operating lease right-of-use assets

532

 

555

 

Goodwill

897

 

824

 

Intangible assets, net

142

 

145

 

Deferred tax assets, net

20

 

64

 

Other assets

589

 

388

 

Total assets

$

7,585

 

$

7,316

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

Current liabilities:

 

 

Accounts payable

$

192

 

$

149

 

Accrued liabilities

541

 

516

 

Long-term debt, current portion

511

 

 

Total current liabilities

1,244

 

665

 

Operating lease liabilities

671

 

695

 

Long-term debt

673

 

1,141

 

Other long-term liabilities

303

 

202

 

Stockholders’ equity

4,694

 

4,613

 

Total liabilities and stockholders’ equity

$

7,585

 

$

7,316

 

Illumina, Inc.

Condensed Consolidated Statements of Income

(In millions, except per share amounts)

(unaudited)

 

 

Three Months Ended

 

Year Ended

 

January 3,
2021

 

December 29,
2019

 

January 3,
2021

 

December 29,
2019

Revenue:

 

 

 

 

 

 

 

Product revenue

$

831

 

 

$

812

 

 

$

2,735

 

 

$

2,929

 

Service and other revenue

122

 

 

141

 

 

504

 

 

614

 

Total revenue

953

 

 

953

 

 

3,239

 

 

3,543

 

Cost of revenue:

 

 

 

 

 

 

 

Cost of product revenue (a)

254

 

 

230

 

 

788

 

 

802

 

Cost of service and other revenue (a)

62

 

 

55

 

 

220

 

 

240

 

Amortization of acquired intangible assets

7

 

 

6

 

 

28

 

 

34

 

Total cost of revenue

323

 

 

291

 

 

1,036

 

 

1,076

 

Gross profit

630

 

 

662

 

 

2,203

 

 

2,467

 

Operating expense:

 

 

 

 

 

 

 

Research and development (a)

200

 

 

161

 

 

682

 

 

647

 

Selling, general and administrative (a)

298

 

 

233

 

 

941

 

 

835

 

Total operating expense

498

 

 

394

 

 

1,623

 

 

1,482

 

Income from operations

132

 

 

268

 

 

580

 

 

985

 

Other income, net

166

 

 

1

 

 

276

 

 

133

 

Income before income taxes

298

 

 

269

 

 

856

 

 

1,118

 

Provision for income taxes

41

 

 

30

 

 

200

 

 

128

 

Consolidated net income

257

 

 

239

 

 

656

 

 

990

 

Add: Net loss attributable to noncontrolling interests

Copyright © acrofan/Business Wire All Right Reserved